People · Operator

Michael P. McCarthy

Named in public records as an officer, director or promoter · active 2011–2022 · Software / Tech, Biotechnology

3
Companies
5
Filings
$33.7M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Acuitive Technologies, Inc.Software / TechSeries A$22.5M$90.3M2021
Pipeline Biomedical, Inc.BiotechnologySeries A$8.0M$289.2M2011
Pipeline Biomedical Holdings, Inc.BiotechnologySeed$3.2M$142.1M2012
Operator network

Michael P. McCarthy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Alex S. Khowaylo · 1 companies · 1 sharedAlex S. KhowayloGary S. Fischetti · 1 companies · 1 sharedGary S. FischettiJames S. Maylayter · 1 companies · 1 sharedJames S. MaylayterMichael S. McCarthy · 1 companies · 1 sharedMichael S. McCart…Vincent S. Forlenza · 1 companies · 1 sharedVincent S. Forlen…Alex Khowaylo · 3 companies · 3 sharedAlex KhowayloDavid S. Washburn · 3 companies · 3 sharedDavid S. WashburnLarry P. Feinberg · 2 companies · 2 sharedLarry P. FeinbergRobert C. Cohen · 2 companies · 2 sharedRobert C. CohenAcuitive Technologies, Inc. · $22.5M raisedAcuitive Technologies…Pipeline Biomedical, Inc. · $8.0M raisedPipeline Biomedical, …Pipeline Biomedical Holdings, Inc. · $3.2M raisedPipeline Biomedical H…Michael P. McCarthyMM
Michael P. McCarthy Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Michael P. McCarthy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
David S. Washburn33
Alex Khowaylo33
Larry P. Feinberg22
Robert C. Cohen22
Michael S. McCarthy11
Vincent S. Forlenza11
Gary S. Fischetti11
James S. Maylayter11
Alex S. Khowaylo11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.